2015
Journal of the American Medical Association (JAMA) publishes discovery of cancer signals found in the blood of asymptomatic women.
2016
GRAIL is founded in January. Early backers include Jeff Bezos and Bill Gates.
2018
At the American Association for Cancer Research (AACR) data supporting multi-cancer early detection is presented. GRAIL enrolls more than 100,000 participants in clinical study program.
2019
In May, GRAIL earns Breakthrough Device designation from FDA for MCED test. Validation data is presented at the ASCO Breakthrough meeting in October.
2020
PATHFINDER study begins enrolling to evaluate MCED test in clinical practice. In March, the Annals of Oncology publishes validation data showing a MCED test detects a common cancer signal across 50+ cancers.
2020
In November, GRAIL partners with UK’s National Health Service.
2021
In December, a manuscript published in AACR models the MCED test showing a reduction in late-stage diagnoses by more than half.
2021
2021: GRAIL announces Providence is first healthcare system to offer Galleri.
2021
In June, the interim analysis for the PATHFINDER Study is presented at American Society of Clinical Oncology (ASCO), which returned results to healthcare providers and reported on the primary objective and the secondary objectives. The same month, Galleri is introduced to the broader public.